Gastrointestinal health care resource utilization with chronic use of COX-2-specific inhibitors versus traditional NSAIDs1 1The Institute for Effectiveness Research, LLC, is a subsidiary of Medco Health Solutions, Inc., a Merck Company.
Laine L, Wogen J, Yu H. Gastrointestinal health care resource utilization with chronic use of COX-2-specific inhibitors versus traditional NSAIDs1 1The Institute for Effectiveness Research, LLC, is a subsidiary of Medco Health Solutions, Inc., a Merck Company. Gastroenterology 2003, 125: 389-395. PMID: 12891540, DOI: 10.1016/s0016-5085(03)00900-4.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAnti-Inflammatory Agents, Non-SteroidalCohort StudiesCost-Benefit AnalysisCyclooxygenase 2Cyclooxygenase 2 InhibitorsCyclooxygenase InhibitorsFemaleGastrointestinal DiseasesHealth ResourcesHumansIsoenzymesLongitudinal StudiesMaleMembrane ProteinsMiddle AgedProstaglandin-Endoperoxide SynthasesRetrospective StudiesConceptsChronic NSAID therapyCoxib therapyNSAID therapyChronic nonsteroidal anti-inflammatory drug (NSAID) therapyNonsteroidal anti-inflammatory drug therapyAnti-inflammatory drug therapyHealth care resource utilizationCOX-2-specific inhibitorsU.S. administrative claims databaseMedco Health SolutionsProportion of patientsAdministrative claims databaseGastrointestinal eventsNewer coxibsInitial prescriptionChronic useClaims databaseDrug therapyClinical trialsDrug costsNew NSAIDClinical practicePatientsTherapyAbstractText
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply